ICTCAR CRC
Alternative Names: Anti- colorectal cancer specific protein (CRCSP) CAR-T cells; Anti- colorectal coupledCAR CAR-T cell therapeutics - Innovative Cellular Therapeutics; Anti-GCC CAR T cells - Innovative Cellular Therapeutics; CRCSP CAR-T cells; GCC19-CART; ICTCAR-CRCLatest Information Update: 20 Jul 2024
At a glance
- Originator Innovative Cellular Therapeutics
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Colorectal cancer
Most Recent Events
- 31 May 2024 Updated adverse events data from the phase I CARAPIA-1 trial in Colorectal cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 05 Apr 2024 Preliminary efficacy and adverse events data from a phase I trial in Colorectal cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 31 Oct 2023 Efficacy and adverse event data from a phase I trial in Colorectal cancer released by Innovative Cellular Therapeutics